Carfilzomib or Bortezomib With Melphalan–Prednisone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomized Phase 3 Study of Carfilzomib or Bortezomib With Melphalan-Prednisone for Transplant-Ineligible, NDMM Patients
Blood 2019 Feb 28;[EPub Ahead of Print], T Facon, JH Lee, P Moreau, R Niesvizky, M Dimopoulos, R Hajek, L Pour, A Jurczyszyn, L Qiu, Z Klippel, A Zahlten-Kumeli, M Osman, B Paiva, J San-MiguelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.